Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial

Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial

Moghadam, M. Ghiti
Vonkeman, H.E.
Klooster, P.M. ten
Tekstra, J.
Schaardenburg, D. van
Starmans-Kool, M.
Brouwer, E.
Bos, R. van den
Lems, W.F.
Colin, E.M.
Allaart, C.F.
Meek, I.L.
Landewe, R.
Moens, H.J.
Riel, P.L.C.M. van
Laar, M.A. van der
Jansen, T.L.Th.A.

January 2016

Item does not contain fulltextOBJECTIVE: Tumor necrosis factor inhibitor (TNFi) biologic agents are ...

Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme

David L Scott
Fowzia Ibrahim
Harry Hill
Brian Tom
Louise Prothero
Rhiannon R Baggott
Ailsa Bosworth
James B Galloway
Sofia Georgopoulou
Naomi Martin
Isabel Neatrour
Elena Nikiphorou
Jackie Sturt
Allan Wailoo
Frances MK Williams
Ruth Williams
Heidi Lempp

August 2021

Background: Rheumatoid arthritis is a major inflammatory disorder and causes substantial disability....

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: A systematic review and economic evaluation

Corbett, M
Soares, M
Jhuti, G
Rice, S
Spackman, E
Sideris, E
Moe-Byrne, T
Fox, D
Marzo-Ortega, H
Kay, L
Woolacott, N
Palmer, S

February 2016

Background: Tumour necrosis factor (TNF)-α inhibitors (anti-TNFs) are typically used when the inflam...

Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews

David L Scott
Fowzia Ibrahim
Vern Farewell
Aidan G O’Keeffe
Margaret Ma
David Walker
Margaret Heslin
Anita Patel
Gabrielle Kingsley

October 2014

Background: Rheumatoid arthritis (RA) is initially treated with methotrexate and other disease-modif...

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: The SWITCH RCT

Brown, S
Everett, CC
Naraghi, K
Davies, C
Dawkins, B
Hulme, C
McCabe, C
Pavitt, S
Emery, P
Sharples, L
Buch, MH

June 2019

This is the final version, also available from NIHR Journals Library via the DOI in this record.Back...

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.

Brown, S
Everett, CC
Naraghi, K
Davies, C
Dawkins, B
Hulme, C
McCabe, C
Pavitt, S
Emery, P
Sharples, L
Buch, MH

January 2018

Rheumatoid arthritis (RA), the most common autoimmune disease in the UK, is a chronic systemic infla...

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT

Sarah Brown
Colin C Everett
Kamran Naraghi
Claire Davies
Bryony Dawkins
Claire Hulme
Christopher McCabe
Sue Pavitt
Paul Emery
Linda Sharples
Maya H Buch

June 2018

Background: Rheumatoid arthritis (RA), the most common autoimmune disease in the UK, is a chronic sy...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

Herwaarden, N. van
Maas, A. van der
Minten, M.J.M.
Hoogen, F.H.J. van den
Kievit, W.
Vollenhoven, R.F. van
Bijlsma, J.W.
Bemt, B.J.F van den
Broeder, A.A. den

January 2015

Contains fulltext : 155038.pdf (publisher's version ) (Open Access)OBJECTIVE: To e...

Anti-TNF agents for rheumatoid arthritis

Thomas, SHL
Seymour, HE
Worsley, A
Smith, JM

January 2001

Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disease with a prevalence of approxi...

Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial

Bouman, C.A.M.
Herwaarden, N. van
Hoogen, F.H.J. van den
Fransen, J.
Vollenhoven, R.F. van
Bijlsma, J.W.
Maas, A.V.
Broeder, A.A. den

January 2017

Item does not contain fulltextOBJECTIVE: Tumour necrosis factor inhibitors (TNFi) are effective in r...

The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.

Kievit, W.
Fransen, J.
Oerlemans, A.J.M.
Kuper, H.H.
Laar, M.A.F.J. van de
Rooij, D.J.R.A.M. de
Gendt, C.M. de
Ronday, K.H.
Jansen, T.L.Th.A.
Oijen, P.C. van
Brus, H.L.
Adang, E.M.M.
Riel, P.L.C.M. van

January 2007

BACKGROUND: Randomised controlled trials (RCTs) evaluating the efficacy of antagonists to tumour nec...

Optimal management of RA patients who require Biologic Therapy (ORBIT) – a randomised controlled, non-inferiority study

Porter, D
van Melckebeke, J
Dale, J
Messow, C
McConnachie, P
Walker, A
Munro, R
McLaren, J
McRorie, E
Packham, J
Buckley, C
Harvie, J
Pitzalis, C
Taylor, P
Choy, E
McInnes, I

January 2016

Background Tumour necrosis factor inhibition (TNFi) and B cell depletion are highly effective treatm...

Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial):Study protocol for a randomised controlled trial

Martin, Naomi H.
Ibrahim, Fowzia
Tom, Brian
Galloway, James
Wailoo, Allan
Tosh, Jonathan
Lempp, Heidi
Prothero, Louise
Georgopoulou, Sofia
Sturt, Jackie
Scott, David L.
Jenner, Richard
Neatrour, Isabel
Baggott, Rhiannon
Kingsley, Gabrielle
Zhong, Yujie
Mian, Aneela

December 2017

Background: Uncontrolled active rheumatoid arthritis can lead to increasing disability and reduced q...

Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis:first-year results of the randomised controlled TARA study

van Mulligen, Elise
de Jong, Pascal Hendrik Pieter
Kuijper, Tjallingius Martijn
van der Ven, Myrthe
Appels, Cathelijne
Bijkerk, Casper
Harbers, Joop B.
de Man, Yael
Molenaar, T.H. Esmeralda
Tchetverikov, Ilja
Goekoop-Ruiterman, Yvonne P.M.
van Zeben, Jende
Hazes, Johanna M.W.
Weel, Angelique E.A.M.
Luime, Jolanda J.

June 2019

OBJECTIVES: The aim of this study is to evaluate the effectiveness of two tapering strategies after ...

Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial

Moghadam, M. Ghiti
Vonkeman, H.E.
Klooster, P.M. ten
Tekstra, J.
Schaardenburg, D. van
Starmans-Kool, M.
Brouwer, E.
Bos, R. van den
Lems, W.F.
Colin, E.M.
Allaart, C.F.
Meek, I.L.
Landewe, R.
Moens, H.J.
Riel, P.L.C.M. van
Laar, M.A. van der
Jansen, T.L.Th.A.

January 2016

Item does not contain fulltextOBJECTIVE: Tumor necrosis factor inhibitor (TNFi) biologic agents are ...

Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme

David L Scott
Fowzia Ibrahim
Harry Hill
Brian Tom
Louise Prothero
Rhiannon R Baggott
Ailsa Bosworth
James B Galloway
Sofia Georgopoulou
Naomi Martin
Isabel Neatrour
Elena Nikiphorou
Jackie Sturt
Allan Wailoo
Frances MK Williams
Ruth Williams
Heidi Lempp

August 2021

Background: Rheumatoid arthritis is a major inflammatory disorder and causes substantial disability....

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: A systematic review and economic evaluation

Corbett, M
Soares, M
Jhuti, G
Rice, S
Spackman, E
Sideris, E
Moe-Byrne, T
Fox, D
Marzo-Ortega, H
Kay, L
Woolacott, N
Palmer, S

February 2016

Background: Tumour necrosis factor (TNF)-α inhibitors (anti-TNFs) are typically used when the inflam...

Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews

David L Scott
Fowzia Ibrahim
Vern Farewell
Aidan G O’Keeffe
Margaret Ma
David Walker
Margaret Heslin
Anita Patel
Gabrielle Kingsley

October 2014

Background: Rheumatoid arthritis (RA) is initially treated with methotrexate and other disease-modif...

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: The SWITCH RCT

Brown, S
Everett, CC
Naraghi, K
Davies, C
Dawkins, B
Hulme, C
McCabe, C
Pavitt, S
Emery, P
Sharples, L
Buch, MH

June 2019

This is the final version, also available from NIHR Journals Library via the DOI in this record.Back...

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.

Brown, S
Everett, CC
Naraghi, K
Davies, C
Dawkins, B
Hulme, C
McCabe, C
Pavitt, S
Emery, P
Sharples, L
Buch, MH

January 2018

Rheumatoid arthritis (RA), the most common autoimmune disease in the UK, is a chronic systemic infla...

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT

Sarah Brown
Colin C Everett
Kamran Naraghi
Claire Davies
Bryony Dawkins
Claire Hulme
Christopher McCabe
Sue Pavitt
Paul Emery
Linda Sharples
Maya H Buch

June 2018

Background: Rheumatoid arthritis (RA), the most common autoimmune disease in the UK, is a chronic sy...

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Porter, Duncan
van Melckebeke, Jurgen
Dale, James
Messow, C. Martina
McConnachie, Alexander
Walker, Andrew
Munro, Robin
McLaren, John
McRorie, Euan
Packham, Jon
Buckley, Christopher D.
Harvie, John
Taylor, Peter
Choy, Ernest
Pitzalis, Costantino
McInnes, Iain B.

July 2016

Background Tumour necrosis factor (TNF) inhibition and B-cell depletion are highly effective treatme...

Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial

Herwaarden, N. van
Maas, A. van der
Minten, M.J.M.
Hoogen, F.H.J. van den
Kievit, W.
Vollenhoven, R.F. van
Bijlsma, J.W.
Bemt, B.J.F van den
Broeder, A.A. den

January 2015

Contains fulltext : 155038.pdf (publisher's version ) (Open Access)OBJECTIVE: To e...

Anti-TNF agents for rheumatoid arthritis

Thomas, SHL
Seymour, HE
Worsley, A
Smith, JM

January 2001

Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disease with a prevalence of approxi...

Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial

Bouman, C.A.M.
Herwaarden, N. van
Hoogen, F.H.J. van den
Fransen, J.
Vollenhoven, R.F. van
Bijlsma, J.W.
Maas, A.V.
Broeder, A.A. den

January 2017

Item does not contain fulltextOBJECTIVE: Tumour necrosis factor inhibitors (TNFi) are effective in r...

The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.

Kievit, W.
Fransen, J.
Oerlemans, A.J.M.
Kuper, H.H.
Laar, M.A.F.J. van de
Rooij, D.J.R.A.M. de
Gendt, C.M. de
Ronday, K.H.
Jansen, T.L.Th.A.
Oijen, P.C. van
Brus, H.L.
Adang, E.M.M.
Riel, P.L.C.M. van

January 2007

BACKGROUND: Randomised controlled trials (RCTs) evaluating the efficacy of antagonists to tumour nec...

Optimal management of RA patients who require Biologic Therapy (ORBIT) – a randomised controlled, non-inferiority study

Porter, D
van Melckebeke, J
Dale, J
Messow, C
McConnachie, P
Walker, A
Munro, R
McLaren, J
McRorie, E
Packham, J
Buckley, C
Harvie, J
Pitzalis, C
Taylor, P
Choy, E
McInnes, I

January 2016

Background Tumour necrosis factor inhibition (TNFi) and B cell depletion are highly effective treatm...

Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial):Study protocol for a randomised controlled trial

Martin, Naomi H.
Ibrahim, Fowzia
Tom, Brian
Galloway, James
Wailoo, Allan
Tosh, Jonathan
Lempp, Heidi
Prothero, Louise
Georgopoulou, Sofia
Sturt, Jackie
Scott, David L.
Jenner, Richard
Neatrour, Isabel
Baggott, Rhiannon
Kingsley, Gabrielle
Zhong, Yujie
Mian, Aneela

December 2017

Background: Uncontrolled active rheumatoid arthritis can lead to increasing disability and reduced q...

Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis:first-year results of the randomised controlled TARA study

van Mulligen, Elise
de Jong, Pascal Hendrik Pieter
Kuijper, Tjallingius Martijn
van der Ven, Myrthe
Appels, Cathelijne
Bijkerk, Casper
Harbers, Joop B.
de Man, Yael
Molenaar, T.H. Esmeralda
Tchetverikov, Ilja
Goekoop-Ruiterman, Yvonne P.M.
van Zeben, Jende
Hazes, Johanna M.W.
Weel, Angelique E.A.M.
Luime, Jolanda J.

June 2019

OBJECTIVES: The aim of this study is to evaluate the effectiveness of two tapering strategies after ...

Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial

Moghadam, M. Ghiti
Vonkeman, H.E.
Klooster, P.M. ten
Tekstra, J.
Schaardenburg, D. van
Starmans-Kool, M.
Brouwer, E.
Bos, R. van den
Lems, W.F.
Colin, E.M.
Allaart, C.F.
Meek, I.L.
Landewe, R.
Moens, H.J.
Riel, P.L.C.M. van
Laar, M.A. van der
Jansen, T.L.Th.A.

January 2016

Item does not contain fulltextOBJECTIVE: Tumor necrosis factor inhibitor (TNFi) biologic agents are ...

Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme

David L Scott
Fowzia Ibrahim
Harry Hill
Brian Tom
Louise Prothero
Rhiannon R Baggott
Ailsa Bosworth
James B Galloway
Sofia Georgopoulou
Naomi Martin
Isabel Neatrour
Elena Nikiphorou
Jackie Sturt
Allan Wailoo
Frances MK Williams
Ruth Williams
Heidi Lempp

August 2021

Background: Rheumatoid arthritis is a major inflammatory disorder and causes substantial disability....

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: A systematic review and economic evaluation

Corbett, M
Soares, M
Jhuti, G
Rice, S
Spackman, E
Sideris, E
Moe-Byrne, T
Fox, D
Marzo-Ortega, H
Kay, L
Woolacott, N
Palmer, S

February 2016

Background: Tumour necrosis factor (TNF)-α inhibitors (anti-TNFs) are typically used when the inflam...

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial

Abstract

Extracted data

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial

Abstract

Extracted data

Related items

Related items